My ears always perk up when takeover rumors swirl, especially when they involve large-cap dividend stocks. The latest big buyout buzz came on Tuesday, when Bristol-Myers Squibb Co (NYSE:BMY) stock popped three …
Dividend Stock
Our hope is we can bring patients who have an official diagnosis of …
cancer cells
Bullish analyst finds the company posting yearly EPS of $3.04 whereas the bearish target is $2.56. A low P/S can also be effective in valuing growth stocks that have suffered a temporary setback. WESPAC Advisors …
Bristol-Myers Squibb
Much ails Bristol-Myers Squibb. The drug maker’s stock has been a bust for investors since August. That’s when the blockbuster immunotherapy …
Bristol Myers Squibb
In this column, I will introduce these two companies, whose destinies are intertwined and, as Bristol-Myers Squibb is an undervalued stock with …
Bristol Myers Squibb
Alison Premo Black, who conducted the analysis. "It is outdated, …
Healthcare Sector Stock